mozavaptan has been researched along with Cyst in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baeßler, B; Benzing, T; Borgal, L; Dafinger, C; Franke, M; Göbel, H; Höhne, M; Koerber, F; Maintz, D; Persigehl, T; Schermer, B; Vechtel, J | 1 |
| de Heer, E; Gansevoort, RT; Meijer, E; Peters, DJ; van Goor, H; Veraar, KA; Versteeg, IB; Zittema, D | 1 |
2 other study(ies) available for mozavaptan and Cyst
| Article | Year |
|---|---|
Magnetic resonance T2 mapping and diffusion-weighted imaging for early detection of cystogenesis and response to therapy in a mouse model of polycystic kidney disease.
Topics: Adult; Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cysts; Diffusion Magnetic Resonance Imaging; Disease Models, Animal; Early Diagnosis; Female; Humans; Image Processing, Computer-Assisted; Kidney; Longitudinal Studies; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Molecular Targeted Therapy; Mutation; NIMA-Related Kinases; Polycystic Kidney Diseases; Proof of Concept Study; Time Factors; Treatment Outcome; Young Adult | 2017 |
Dose-Titrated Vasopressin V2 Receptor Antagonist Improves Renoprotection in a Mouse Model for Autosomal Dominant Polycystic Kidney Disease.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cysts; Disease Models, Animal; Drinking; Female; Kidney; Male; Mice, Knockout; Organ Size; Polycystic Kidney, Autosomal Dominant; Protein Kinase C; Time Factors; Water | 2016 |